Skip to main content
SpringerLink
Log in

Serum IL-8 and IL-12 levels in breast cancer

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Interleukins (ILs) are known to play a fundamental role in cancer. We investigated the serum levels of IL-8 and IL-12, in breast cancer patients, and their relationship with the prognostic parameters and therapy. Fortyeight patients with pathologically verified breast carcinoma and 21 healthy controls were enrolled into the study. Serum samples were obtained at baseline and after two cycles of chemotherapy. Serum IL-8 and IL-12 levels were determined using enzyme-linked immunosorbent assay (ELISA). There was no significant difference in the baseline serum IL-8 and IL-12 levels between breast cancer patients and healthy controls (p = 0.365 andp = 0.871, respectively), no significant correlation between the prognostic parameters and the serum IL-8, IL-12 levels. However, in the subgroup consisting of metastatic breast cancer patients, baseline serum IL-8 levels were significantly higher compared with non-metastatic disease (p = 0.047). Anthracycline-based chemotherapy and the addition of taxane did not change the levels of both serum IL-8 and IL-12. Serum IL-8 level may be useful in determining metastatic breast cancer. Larger studies are needed to confirm this finding.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Suri C, et al. Increased vascularization in mice overexpressing angiopoietin-1.Science 1998;182: 468–471.

    Article  Google Scholar 

  2. Teicher BA, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents.Int J Cancer 1994;57: 1–6.

    Article  Google Scholar 

  3. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients.Rocz Akad Med Bialymst 2003;48: 82–84.

    PubMed  CAS  Google Scholar 

  4. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.Annu Rev Immunol 1995;13: 251–276.

    PubMed  CAS  Google Scholar 

  5. Blanks RE, Patel PM, Selby PJ. Interleukin-12: a new clinical player in cytokine therapy.Br J Cancer 1995;71: 655–659.

    Google Scholar 

  6. O’Hara RJ, et al. Advanced colorectal cancer is associated with impaired Interleukin 12 and enhanced Interleukin 10 production.Clin Cancer Res 1998;4: 1943–1948.

    PubMed  CAS  Google Scholar 

  7. Nakayama Y, et al. Serum levels of interleukin-12 in patients with gastrointestinal cancer.Anticancer Res 2000;20: 635–640.

    PubMed  CAS  Google Scholar 

  8. Merendino RA, et al. Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients.Immunol Lett 1999;68: 355–358.

    Article  PubMed  CAS  Google Scholar 

  9. Voest EE, et al. Inhibition of angiogenesis in vivo by interleukin 12.J Natl Cancer Inst 1995;87: 581–586.

    Article  PubMed  CAS  Google Scholar 

  10. Cavallo F, et al. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin-12.Cancer Res 1999;59: 414–421.

    PubMed  CAS  Google Scholar 

  11. Strieter RM, et al. Interleukin-8. A corneal factor that induces neovascularization.Am J Pathol 1992;141: 1279–1284.

    PubMed  CAS  Google Scholar 

  12. Belperio JA, et al. CXC chemokines in angiogenesis.J Leukocyte Biol 2000;68: 1–8.

    PubMed  CAS  Google Scholar 

  13. Kunz M, et al. Anoxia-induced up-regulation of interleukin-8 in human malign melanoma. A potential mechanism for high tumor aggressiveness.Am J Pathol 1999;155: 753–763.

    PubMed  CAS  Google Scholar 

  14. Benoy IH, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival.Clin Cancer Res 2004;10: 7157–7162.

    Article  PubMed  CAS  Google Scholar 

  15. Pusztai L, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.Cytokines 2004;25: 94–102.

    Article  CAS  Google Scholar 

  16. De Larco JE, et al. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells.Am J Pathol 2001;158: 639–646.

    PubMed  Google Scholar 

  17. Yokoe T, Lino Y, Morishita Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report.Breast Cancer 2000;7: 187–190.

    Article  PubMed  CAS  Google Scholar 

  18. Lissoni P, et al. Interleukin-12 in early or advanced cancer patients.Eur J Cancer 1997;33: 1703–1705.

    Article  PubMed  CAS  Google Scholar 

  19. Zeimet AG, et al. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer.J Clin Oncol 1998;16: 1861–1868.

    PubMed  CAS  Google Scholar 

  20. Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients: relation to the tumour stage and previous therapy.Biomed Pharmacother 2001;55: 111–116.

    Article  PubMed  CAS  Google Scholar 

  21. Urosevic M, Dummer R. HLA-G and IL-10 expression in human cancer.Sem Cancer Biol 2003;13: 337–342.

    Article  CAS  Google Scholar 

  22. Lissoni P, et al. Physiopathology of IL-12 in early or advanced cancer patients and their variations with surgery and immunotherapy.J Biol Regul Homeost Agents 1998;12: 38–41.

    PubMed  CAS  Google Scholar 

  23. Miller LT, et al. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue.Anticancer Res 1998,18: 77–81.

    PubMed  CAS  Google Scholar 

  24. Okamoto M, et al. Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck patients.Anticancer Drugs 2000;11: 165–173.

    Article  PubMed  CAS  Google Scholar 

  25. Uslu R, et al. Predictive value of serum interleukin-8 in ovarian cancer patients treated with paclitaxel-containing regimens.Int J Gynecol Cancer 2005;15: 240–245.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute Of Oncology, Istanbul University, Istanbul, Turkey

    Duygu Derin, Hilal Oguz Soydinc, Nese Guney, Faruk Tas, Hakan Camlica, Derya Duranyildiz, Vildan Yasasever & Erkan Topuz

Authors
  1. Duygu Derin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hilal Oguz Soydinc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nese Guney
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Faruk Tas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hakan Camlica
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Derya Duranyildiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vildan Yasasever
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Erkan Topuz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Duygu Derin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Derin, D., Soydinc, H.O., Guney, N. et al. Serum IL-8 and IL-12 levels in breast cancer. Med Oncol 24, 163–168 (2007). https://doi.org/10.1007/BF02698035

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02698035

Key words

Search

Navigation